Avraham Gabay compensation by year
ORAMED PHARMACEUTICALS Summary Compensation Table · all 2 fiscal years held| Component | FY2019 | FY2020 |
|---|---|---|
| Salary | $32,122 | $130,554 |
| Bonus | $0 | $15,591 |
| Stock awards | $0 | — |
| Option awards | $73,928 | $0 |
| Non-equity incentive | $0 | — |
| Pension and deferred compensation | $0 | — |
| All other | $9,441 | $44,912 |
| Total | $115,491 | $191,418 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ORAMED PHARMACEUTICALS INC. DEF 14A filed July 28, 2021, accession 0001213900-21-039099, and prior-year filings.
How this page was built: the ORAMED PHARMACEUTICALS INC. filed document, accession 0001213900-21-039099. Every figure is read from that document and cited to the page and table it appears in. Filed July 28, 2021.
Equity holdings
unvested awards at FY2020 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 27,750 | — | $3.55 |
Per the Outstanding Equity Awards at Fiscal Year-End table in ORAMED PHARMACEUTICALS INC.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
16 Form 4 lines since the FY2020 proxy (filed July 28, 2021)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-11-12 | Grant or award | — | 242,000 | — | 1,460,076 |
| 2026-11-12 | Grant or award | — | 357,000 | — | 1,218,076 |
| 2026-10-01 | Sale | 10b5-1 | 20,000 | $4.51 | 861,076 |
| 2026-09-24 | Grant or award | — | 209,291 | — | 881,076 |
| 2026-07-01 | Sale | — | 73,360 | $4.51 | 671,785 |
| 2026-03-17 | Grant or award | — | 95,889 | $0.00 | 745,145 |
| 2026-01-22 | Exercise or conversion | — | 19,000 | $0.00 | 649,256 |
| 2026-01-22 | Exercise or conversion derivative | — | 19,000 | $0.00 | 0 |
The 8 most recent of 16 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
ORAMED PHARMACEUTICALS’s named executive officers, FY2020
as the company reported each| Named executive officer | Role | FY2020 total |
|---|---|---|
| Nadav Kidron | President, Chief Executive Officer and director (7) | $1,767,851 |
| Miriam Kidron | Chief Scientific Officer and director (8) | $688,700 |
| Joshua Hexter | Chief Operating & Business Officer (10) | $608,833 |
| Avraham Gabay · this page | Chief Financial Officer | $191,418 |
The full ORAMED PHARMACEUTICALS compensation record
free company briefThis page is one person within ORAMED PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the ORAMED PHARMACEUTICALS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ORAMED PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.